SearchDictionaryMobileLogin

Gabriel N Hortobagyi Selected Research

Drug Therapy (Chemotherapy)

09/2008Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
04/2008Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
03/2008HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
01/2008PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
01/2008Evaluation of biological pathways involved in chemotherapy response in breast cancer.
01/2008Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
10/2007Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
09/2007Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
07/2007Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
07/2007Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
07/2007Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
04/2007Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
02/2007Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
01/2007Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
12/2006DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
12/2006African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy.
10/2006Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
09/2006Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
09/2006Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
09/2006A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
07/2006Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
06/2006Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
02/2006Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
12/2005Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
12/2005The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
11/2005Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
10/2005Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
10/2005Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
08/2005Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
08/2005Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
08/2005Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
06/2005Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
06/2005Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
01/2005Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
01/2005Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer.
12/2004Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
11/2004Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
11/2004The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
10/2004Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
07/2004Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA.
06/2004Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
06/2004Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.
05/2004T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
04/2004Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
01/2004Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
10/2003Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
10/2003Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
09/2003Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
04/2003Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
01/2003First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.
01/2003Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
11/2002Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
10/2002Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
07/2002Neoadjuvant chemotherapy for operable breast cancer.
06/2002Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

Articles by Research Topic

Disease

96Breast Neoplasms (Breast Cancer)
10/2008 - 01/2002
22Carcinoma (Carcinomatosis)
06/2007 - 05/2002
16Neoplasms (Cancer)
06/2008 - 06/2002
6Neoplasm Metastasis (Metastasis)
01/2008 - 08/2005
2Residual Neoplasm
07/2007 - 10/2006
2Lobular Carcinoma
12/2006 - 01/2005
2Male Breast Neoplasms (Male Breast Cancer)
07/2006 - 06/2002
1Obesity
09/2008
1Pancreatic Neoplasms (Pancreatic Cancer)
09/2008
1Osteonecrosis (Kienbock's Disease)
06/2008
1Phyllodes Tumor (Cystosarcoma Phylloides)
11/2007
1Heart Failure
09/2007
1Inflammation
08/2007
1Noninfiltrating Intraductal Carcinoma (DCIS)
07/2007
1Ductal Carcinoma
12/2006
1Vasculitis (Vasculitides)
07/2006
1Death (Near-Death Experience)
03/2005
1Pneumonia (Pneumonitis)
11/2004
1Colitis
10/2004
1Neutropenia
01/2003
1Ovarian Neoplasms (Ovarian Cancer)
11/2002
1Pathologic Constriction (Stenosis)
06/2002

Drug/Important Bio-Agent (IBA)

13Paclitaxel (Taxol)FDA LinkGeneric
03/2008 - 05/2002
13Doxorubicin (Adriamycin)FDA LinkGeneric
11/2007 - 01/2002
9docetaxel (Taxotere)FDA Link
06/2008 - 01/2002
7trastuzumab (Herceptin)FDA Link
01/2007 - 04/2002
7Fluorouracil (Carac)FDA LinkGeneric
01/2007 - 01/2002
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2007 - 01/2002
6Biological Markers (Surrogate Marker)IBA
12/2006 - 06/2002
5Estrogens (Estrogen)FDA Link
10/2008 - 07/2003
4Epidermal Growth Factor Receptor (EGF Receptor)IBA
10/2007 - 06/2005
4taxaneIBA
08/2007 - 02/2002
3capecitabine (Xeloda)FDA Link
08/2007 - 09/2003
3Epirubicin (Ellence)FDA LinkGeneric
01/2007 - 06/2005
2DiphosphonatesIBA
06/2008 - 05/2008
2erlotinib (CP 358,774)FDA Link
08/2007 - 06/2007
2HormonesIBA
05/2007 - 03/2005
2tau Proteins (tau Protein)IBA
04/2007 - 06/2005
2TamoxifenFDA LinkGeneric
07/2006 - 01/2002
2gemcitabineFDA Link
09/2003 - 05/2002
2vinorelbine (Navelbine)FDA LinkGeneric
05/2002 - 01/2002
25-ethynyluracil (eniluracil)IBA
05/2002 - 02/2002
1Lysine (L-Lysine)FDA Link
09/2008
1Histones (Histone)IBA
09/2008
1lapatinib (GW572016)FDA Link
07/2008
1Cisplatin (Platino)FDA LinkGeneric
05/2008
1Dacarbazine (DIC)FDA LinkGeneric
11/2007
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
10/2007
1ixabepilone (BMS 247550)FDA Link
08/2007
1I-kappa B KinaseIBA
08/2007
1Cyclin-Dependent Kinase 2IBA
08/2007
1DNA (Deoxyribonucleic Acid)IBA
12/2006
1CyclinsIBA
10/2006
1Phosphotransferases (Kinase)IBA
10/2006
1temozolomide (Temodar)FDA Link
09/2006
1Aromatase (CYP19)IBA
07/2006
1Leuprolide (Lupron)FDA LinkGeneric
07/2006
1Cytosine DeaminaseIBA
01/2006
1EndostatinsIBA
01/2006
1Transcription Factors (Transcription Factor)IBA
12/2005
1ParaffinIBA
10/2005
1albumin-bound paclitaxelFDA Link
09/2005
1tariquidar (XR9576)IBA
08/2005
1P-GlycoproteinIBA
08/2005
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2005
1Carmustine (FIVB)FDA Link
11/2004
1Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
11/2004
1TaxoidsIBA
07/2004
1Protein Kinases (Protein Kinase)IBA
02/2004
1Proteins (Proteins, Gene)IBA
01/2004
1fludarabineIBA
11/2003
1Melphalan (Alkeran)FDA Link
11/2003
1NF-kappa B (NF-kB)IBA
11/2003
1sulindac sulfone (exisulind)IBA
09/2003
1pegylated liposomal doxorubicinIBA
09/2003
1DX 8951 (DX 8951f)IBA
09/2003
1Filgrastim (Neupogen)FDA Link
07/2003
1RNA (Ribonucleic Acid)IBA
06/2003
1bexarotene (LGD1069)FDA Link
03/2003
1Estrogen ReceptorsIBA
03/2003
1Cyclin EIBA
11/2002
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
11/2002
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
11/2002
1annamycinIBA
07/2002
1anastrozole (Arimidex)FDA Link
06/2002
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2002

Therapy/Procedure

55Drug Therapy (Chemotherapy)
09/2008 - 06/2002
9Adjuvant Chemotherapy
10/2008 - 05/2002
6Mastectomy (Mammectomy)
12/2006 - 07/2002
5Neoadjuvant Therapy
03/2008 - 06/2005
2Adjuvant Radiotherapy
10/2005 - 03/2005
1Biological Therapy
05/2007
1Hematopoietic Stem Cell Transplantation
11/2004
1Aftercare (After-Treatment)
02/2004
1Stem Cell Transplantation
11/2003
1Estrogen Replacement Therapy
11/2002